TABLE 4.
Brain NAT amounts from control, acutely PF-3845-treated (10 mg/kg i.p., 3 h), chronically PF-3845-treated (10 mg/kg i.p., once per day, 6 days), or FAAH(−/−) mice
| Group | C16:0 | C18:0 | C18:1 | C18:2 | C20:4 | C22:0 | C22:6 |
|---|---|---|---|---|---|---|---|
| pmol/g | |||||||
| Control | 184 ± 20 | 148 ± 25 | 124 ± 17 | 5 ± 2 | 83 ± 23 | 20 ± 6 | 38 ± 3 |
| Acute PF-3845 | 142 ± 20 | 143 ± 26 | 99 ± 16 | 16 ± 2a | 31 ± 3b | 15 ± 3 | 50 ± 6 |
| Chronic PF-3845 | 155 ± 65 | 600 ± 11b | 362 ± 38a | 30 ± 3b | 48 ± 1a | 529 ± 113a | 88 ± 10a |
| FAAH(−/−) | 283 ± 23 | 438 ± 30b | 207 ± 13a | 14 ± 2a | 35 ± 1b | 680 ± 62b | 59 ± 7 |
All values have units of pmol/g tissue. Data are presented as means ± SEM, n = 4–6/group.
a
P < 0.05 for acute PF-3845, chronic PF-3845, or FAAH(−/−) versus control.
b
P < 0.01 for acute PF-3845, chronic PF-3845, or FAAH(−/−) versus control.